tetano
Editor, Senior Moderator
J Heart Lung Transplant
. 2022 Oct 5;S1053-2498(22)02164-7.
doi: 10.1016/j.healun.2022.09.020. Online ahead of print.
Heart transplantation for COVID-19 myopathy in the United States
George Gill[SUP] 1 [/SUP], Amy Roach[SUP] 1 [/SUP], Georgina Rowe[SUP] 1 [/SUP], Dominic Emerson[SUP] 1 [/SUP], Jon Kobashigawa[SUP] 2 [/SUP], Errol P Lobo[SUP] 3 [/SUP], Fardad Esmailian[SUP] 1 [/SUP], Michael E Bowdish[SUP] 1 [/SUP], Joanna Chikwe[SUP] 4 [/SUP]
Affiliations
Abstract
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.
Keywords: COVID-19; cardiac surgery; critical care; heart failure; heart transplant.
. 2022 Oct 5;S1053-2498(22)02164-7.
doi: 10.1016/j.healun.2022.09.020. Online ahead of print.
Heart transplantation for COVID-19 myopathy in the United States
George Gill[SUP] 1 [/SUP], Amy Roach[SUP] 1 [/SUP], Georgina Rowe[SUP] 1 [/SUP], Dominic Emerson[SUP] 1 [/SUP], Jon Kobashigawa[SUP] 2 [/SUP], Errol P Lobo[SUP] 3 [/SUP], Fardad Esmailian[SUP] 1 [/SUP], Michael E Bowdish[SUP] 1 [/SUP], Joanna Chikwe[SUP] 4 [/SUP]
Affiliations
- PMID: 36682895
- DOI: 10.1016/j.healun.2022.09.020
Abstract
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.
Keywords: COVID-19; cardiac surgery; critical care; heart failure; heart transplant.